Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
Date:9/14/2007

ported an increased level of

genital arousal, an increased level of sexual desire and a higher

incidence of engaging in sexual activity compared to placebo.

-- The announcement of results from two Phase 2B trials evaluating

bremelanotide for ED, with one trial limited to non-diabetic patients

and the other to diabetic patients. The primary objective of the

studies was to characterize the efficacy and safety of bremelanotide in

these two ED populations and to identify the doses to use in further

development.

-- The completion of an exclusive global licensing and research

collaboration agreement with AstraZeneca AB to discover, develop and

commercialize small molecule compounds that target melanocortin

receptors for the treatment of obesity, diabetes and related metabolic

syndrome and the receipt of an up-front payment of $10 million.

-- The February 2007 sale of 13.75 million shares of its common stock in

an underwritten offering at $2.00 per share, resulting in net proceeds

to the Company of $25.5 million, after commissions and expenses.

-- The announcement in August 2007 of a delay in plans for the initiation

of Phase 3 clinical trials with bremelanotide for the treatment of ED

as a result of responses from representatives of the U.S. Food and Drug

Administration, which raised serious concerns about the acceptable

benefit/risk ratio to support the progression of bremelanotide into

Phase 3 studies for ED as a first-line therapy in the general

population.

-- The pending termination of the Collaborative Development and Marketing

Agreement with King, effective December 2007, upon which Palatin will

reacquire sole ownership of all rights to bremelanotide, without any

obligation for future payments to King. King has no financial

obligati
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 international ... Adult Stem Cell Technology Center, LLC ( ASCTC ) ... unique property of adult tissue stem cells. His ... the Past, Important for the Future,” embodied the essence ... the address at the 4th World Congress on Cell ...
(Date:12/24/2014)... 2014 The report provides ... its definition, classification, application and industry overview. ... process, and product cost structure. Production is ... analysis also covers upstream raw materials, equipment, ... trend and proposals. In the end, the ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... ... listed below, ST. LOUIS, June 13 ETHEX Corporation announced ... mg extended release tablets, and specific lots of morphine,sulfate 30 mg ... oversized tablets. Oversized tablets may contain as,much as two times the ...
... Conn., June 13 Alexion,Pharmaceuticals, Inc. (Nasdaq: ... President and Chief Financial Officer of Alexion,Pharmaceuticals, will ... Stock,Conference in Chicago at 9:10 a.m., local time ... An audio webcast of Mr. Sinha,s remarks will ...
... 13 Best Practices, LLC,s latest,benchmarking study explains ... CI operations while working within defined,guidelines., Particular ... is being,collected, and how CI groups work within ... collection that are in the best interests of,the ...
Cached Biology Technology:ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4Pharmaceutical Competitive Intelligence Excellence: Optimizing Data Collection with Approved Guidelines 2
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... available amount of fossil fuels is limited and their ... The generation of fuels from biomass as an alternative ... Chemie , Johannes A. Lercher and his team at ... catalytic process that allows the effective conversion of biopetroleum ...
... KAN. -- A Kansas State University graduate student sees the ... Smith, master,s student in civil engineering, Independence, Mo., is working ... to improve the quality of unpaved roads throughout Kansas. ... in Kansas are unpaved, Smith said. "One of the ...
... advancing field of tissue injury and repair has an ... will report the latest research findings, innovative wound care ... skin and tissue regeneration to optimize patient outcomes. The ... is an Official Publication of the Wound Healing ...
Cached Biology News:Algae for your fuel tank 2The path less traveled: Research is driving solutions to improve unpaved roads 2The path less traveled: Research is driving solutions to improve unpaved roads 3New publication fosters improved wound care for ulcers, limb salvage, burns, trauma, and more 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: